Autolus Therapeutics (NASDAQ:AUTL) inks an agreement with Tokyo-based Noile-Immune Biotech for rights to develop CAR T therapies using Noile’s PRIME (proliferation-inducing and migration-enhancing) technology secreting both IL-7 and CCL19.
PRIME is designed to improve proliferation and trafficking into solid tumors of both engineered CAR T cells and patients’ own T cells.
Under the terms of the agreement, Autolus will pay Noile-Immune an undisclosed amount of upfront cash, milestones and royalties on net sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.